Vireo Growth (VREOF) Liabilities and Shareholders Equity (2020 - 2026)

Vireo Growth (VREOF) reported Liabilities and Shareholders Equity of $928.8 million for Q1 2026, up 235.25% on a YoY basis from $277.0 million in Q1 2025, and up 13.66% sequentially from $817.2 million in Q4 2025.

Vireo Growth (VREOF) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends

Vireo Growth (VREOF) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $928.8 million in Q1 2026.

  • For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 235.25% year-over-year to $928.8 million; the trailing twelve-month figure through Mar 2026 stood at $3.1 billion (up 226.56% YoY), and the FY2025 full-year result was $817.2 million, up 193.05% from the prior year.
  • Liabilities and Shareholders Equity rose to $928.8 million in Q1 2026, from $817.2 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $928.8 million in Q1 2026 to a low of $158.6 million in Q1 2023.
  • A 5-year average of $327.1 million and a median of $190.9 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
  • Across the five-year window, Liabilities and Shareholders Equity dropped 4.68% in 2022 and jumped 250.19% in 2025, its largest moves.
  • Tracing VREOF's Liabilities and Shareholders Equity over 5 years: stood at $159.2 million in 2022, then advanced by 15.15% to $183.3 million in 2023, then jumped by 52.16% to $278.9 million in 2024, then surged by 193.05% to $817.2 million in 2025, then gained by 13.66% to $928.8 million in 2026.
  • Business Quant data shows VREOF's Liabilities and Shareholders Equity at $928.8 million in Q1 2026, $817.2 million in Q4 2025, and $678.9 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 43.40 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 40.04 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 15.15 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 98.91 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 6.71 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - 69.30 Bn
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 36.83 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 4.91 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 13.22 Bn
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn 928.80 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 928.80 Mn
Dec 31, 2025 817.20 Mn
Sep 30, 2025 678.92 Mn
Jun 30, 2025 659.34 Mn
Mar 31, 2025 277.05 Mn
Dec 31, 2024 278.86 Mn
Sep 30, 2024 193.87 Mn
Jun 30, 2024 194.68 Mn
Mar 31, 2024 190.88 Mn
Dec 31, 2023 183.26 Mn
Sep 30, 2023 171.67 Mn
Jun 30, 2023 165.95 Mn
Mar 31, 2023 158.63 Mn
Dec 31, 2022 159.16 Mn
Sep 30, 2022 173.32 Mn
Jun 30, 2022 168.82 Mn
Mar 31, 2022 160.73 Mn
Dec 31, 2021 166.97 Mn
Sep 30, 2021 164.16 Mn
Jun 30, 2021 112.68 Mn